News
TIL
19.88
+4.30%
0.82
Weekly Report: what happened at TIL last week (0303-0307)?
Weekly Report · 4d ago
Instil Bio Non-GAAP EPS of -$1.82
Seeking Alpha · 03/05 15:17
Instil Bio Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Dow Jones · 03/05 12:22
HC Wainwright & Co. Reiterates Buy on Instil Bio, Maintains $110 Price Target
Benzinga · 03/05 12:12
Instil Bio’s Promising Pipeline and Strategic Collaborations Drive Buy Rating
TipRanks · 03/05 11:39
Instil Bio, Inc. (TIL) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Press release · 03/04 23:21
JMP Securities Keeps Their Hold Rating on Instil Bio (TIL)
TipRanks · 03/04 18:26
Instil Bio, Inc. Q4 Loss Declines
NASDAQ · 03/04 12:39
Instil Bio Reports 2024 Financial Results and Outlook
TipRanks · 03/04 12:29
Instil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last year
TipRanks · 03/04 12:18
Instil Bio Q4 2024 GAAP EPS $(1.82) Beats $(3.22) Estimate, Instil Had $115.1M In Total Cash, Cash Equivalents, Restricted Cash And Marketable Securities, That Is Expected To Fund Its Current Operating Plan Beyond 2026
Benzinga · 03/04 12:13
*Instil Bio 4Q Loss/Shr $1.82 >TIL
Dow Jones · 03/04 12:10
*Instil Bio 4Q Adj Loss/Shr $1.08 >TIL
Dow Jones · 03/04 12:10
*Instil Bio 4Q Research and Development Expenses $1.1M >TIL
Dow Jones · 03/04 12:10
Press Release: Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Dow Jones · 03/04 12:09
Weekly Report: what happened at TIL last week (0224-0228)?
Weekly Report · 03/03 09:46
Jefferies Predicts Up to ~500% Jump for These 2 ‘Strong Buy’ Stocks
TipRanks · 03/01 11:15
Instil Bio: Time To Hop On The Summit Wave?
Seeking Alpha · 02/24 15:39
Weekly Report: what happened at TIL last week (0217-0221)?
Weekly Report · 02/24 09:46
Weekly Report: what happened at TIL last week (0210-0214)?
Weekly Report · 02/17 09:45
More
Webull provides a variety of real-time TIL stock news. You can receive the latest news about Instil Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TIL
More
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.